Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology AGM Information 2025

Apr 4, 2025

3535_rns_2025-04-04_16023246-05d3-4f3e-89a2-8967ec21d760.html

AGM Information

Open in viewer

Opens in your device viewer

AQUA BIO TECHNOLOGY ASA - RESULT OF SUBSEQUENT OFFERING - UPDATE OF PROPOSAL FOR THE EXTRAORDINARY GENERAL MEETING

AQUA BIO TECHNOLOGY ASA - RESULT OF SUBSEQUENT OFFERING - UPDATE OF PROPOSAL FOR THE EXTRAORDINARY GENERAL MEETING

4.4.2025 08:00:00 CEST | Aqua Bio Technology ASA | Additional regulated

information required to be disclosed under the laws of a member state

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the "

Company") on 27 March 2025 regarding a subsequent offering with gross proceeds

of up to NOK 10,000,000 through issuance of up to 20,000,000 new shares at a

subscription price of NOK 0.50 per share (the "Subsequent Offering").

In the Subsequent Offering, the shareholders of the Company as of 11 March 2025

(as registered in the VPS on 13 March 2025), except: (i) shareholders that

subscribed for shares in the private placement placed on 11 March 2025, and (ii)

shareholders who are resident in a jurisdiction where such offering would be

unlawful, or would require any prospectus filing, registration or similar action

(the "Eligible Shareholders"), received subscription rights giving preferential

rights to subscribe for and be allocated new shares in the Subsequent Offering

(the "Offer Shares"). In addition, certain groups of investors, as described in

the stock exchange notice dated 27 March 2025 were given a secondary right to

subscribe for Offer Shares not subscribed for by the Eligible Shareholders ("

Secondary Subscribers").

The application period in the Subsequent Offering ended on 3 April 2025 at 16.30

CEST. At the end of the application period, the Company had received

applications for 4,111,975 Offer Shares. The new shares will be subscribed both

through subscription rights and from Secondary Subscribers.

The Company's board of directors (the "Board") has now allocated shares in the

Subsequent Offering, which implies that the Company shall issue 4,111,975 Offer

Shares. The Board has allocated 3,742,741 Offer Shares to Eligible Shareholders

and 369,234 Offer Shares to Secondary Subscribers. Allocation letters, regarding

the number of shares allocated and the subscription amount to be paid, will be

distributed to the subscribers shortly.

As the subscription price of the Offer Shares is lower than the current par

value of the Company's shares, the Company must carry out a share capital

decrease to reduce the par value of the Company's shares to NOK 0.50 per share

(the "Share Capital Decrease").

In order to issue Offer Shares to the applicants, the general meeting of the

Company (to be held on 9 April 2025) must pass a resolution to increase the

Company's share capital (the "Share Capital Increase"). In the notice to the

general meeting minutes, the resolution is given with a minimum and maximum

increase of the share capital. Given that the exact number of Offer Shares is

now known, the Company's Board of Directors has now resolved to update its

proposal to the general meeting, as evident from the attached document.

Completion of the Subsequent Offering is subject to; (i) all necessary corporate

resolutions for consummating the Subsequent Offering, including both the Share

Capital Decrease and the Share Capital Increase, having been validly passed,

(ii) the Share Capital Decrease being registered as completed in the Norwegian

Register of Business Enterprises, (iii) valid subscription of the Offer Shares

and the allocated Offer Shares having been fully paid, and (iv) registration of

the Share Capital Increase in the Norwegian Register of Business Enterprises.

DISCLOSURE REGULATION

For further information, please contact Fredrik Henriksen, CEO, Phone +47 900 20

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on Euronext Expand.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Fredrik Henriksen, CEO, Aqua Bio Technology ASA, +47 90 02 00 78,

[email protected]

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology ASA (ABT) is a distribution group in skincare and nonfood.

The group has distribution towards B2C, B2B, B2B2, and freight, customs, and

logistics services. The group also develops sustainable biotechnology for use in

skincare products. Aqua Bio Technology is listed on the Euronext Expand market

of the Oslo Stock Exchange.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/18483876/5912/Download%20announce

ment%20as%20PDF.pdf

Updated proposal for item 6 on the agenda.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/18483876/5911/Updated%20proposal%

20for%20item%206%20on%20the%20agenda.pdf